FDA Approves Aducanumab — A Controversial Drug For Alzheimer's

FDA Approves Aducanumab — A Controversial Dru...

Up next

Coffee is complex. Can science standardize it for the better?

Ask any coffee aficionado, and they’ll tell you: A good cup is about more than the beans. The flavor is affected by lots of things – the roast and fermentation of the beans, the coarseness of the grind, the brewing temperature and even the chemicals in the water used to brew it. ...  Show more

NASA is practicing moonwalks. When are we going back?

After the success of Artemis II, we at Short Wave definitely have moon fever. So, we brought NPR science correspondent Nell Greenfieldboyce onto the show to talk about where we’re headed. What will future Artemis missions look like and what needs to happen next for people to be a ...  Show more

Recommended Episodes

Controversial new Alzheimer's drug in the spotlight
Business Daily

After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ...  Show more

'Some Hope Is Better Than Having No Hope'
The Daily

When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.

But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ...

  Show more

This Is a Very Weird Moment in the History of Drug Laws
The Ezra Klein Show

Drug policy feels very unsettled right now. The war on drugs was a failure. But so far, the war on the war on drugs hasn’t entirely been a success, either.

Take Oregon. In 2020, it became the first state in the nation to decriminalize hard drugs. It was a paradigm shift ...

  Show more

Declining ALS Patients Are Waiting On The FDA's Next Move
Big Take

For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon an ...  Show more